Recent Updates
Recently added Catalysts
FHTX Positive Sentiment Score: 75/100

Foghorn Therapeutics to Participate in the BMO Oncology Summit

Tuesday, October 1, 2024 1 min read
Key Takeaway: Foghorn Therapeutics Inc. will participate in the BMO Oncology Summit on October 8, 2024, in New York, NY. The company focuses on developing innovative medicines aimed at correcting abnormal gene expression to treat serious diseases. Their Gene Traffic Control platform promises to advance treatment options, particularly in oncology, and has a broad pipeline that may impact a wide array of diseases.

Market Sentiment Analysis

POSITIVE FACTORS

  • Participation in a reputable oncology summit highlights industry recognition.
  • Potential for transformative medicines targeting serious diseases.
  • Strong focus on oncology with a broad pipeline of treatments.

Full Press Release Details

CAMBRIDGE, Mass., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced management's participation in investor meetings at the BMO Oncology Summit being held Tuesday, October 8, 2024, in New York, NY. With an initial focus in oncology, Foghorn’s Gene Traffic Control® platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases.
About Foghorn Therapeutics
Karin Hellsvik, Foghorn Therapeutics Inc. (Investors & Media)
khellsvik@foghorntx.com

Frequently Asked Questions

What is Foghorn Therapeutics known for?

Foghorn Therapeutics develops medicines that correct abnormal gene expression.

When is Foghorn participating in investor meetings?

Foghorn will attend the BMO Oncology Summit on October 8, 2024.

What is the focus of Foghorn’s research?

Foghorn initially focuses on oncology treatments for various diseases.

What platform does Foghorn use for its therapies?

Foghorn uses the Gene Traffic Control® platform for its pipeline.

Where is Foghorn Therapeutics located?

Foghorn Therapeutics is based in Cambridge, Massachusetts.

Tags: FHTX Viatris Investor Conferences Healthcare Foghorn Therapeutics oncology summit gene expression New York
Last updated: Oct 1, 2024